• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of written meeting responses that were sent greater than two FDA business days in advance of the meeting (1)

Dictionary: This measure focuses on the timeliness of providing written responses to pre-meeting questions that are submitted by sponsors before a scheduled face-to-face meeting. OBRR's goal is to provide comprehensive responses prior to the meeting to further advance the exchange of information leading to more efficient product development.

Information is current as of September 30, 2012

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetPercent
Oct 20117585
Nov 20117572
Dec 201175100
Jan 20127560
Feb 20127580
Mar 20127578
Apr 20127583
May 20127555
Jun 20127575
Jul 20127557
Aug 20127525
Sep 20127586

FY 2012 Overall: 70%

Footnotes

  • (1) FDA business days are Monday through Friday.

Number of written meeting responses during the month that were faxed/emailed greater than two FDA business days in advance of the meeting

Fiscal Year - 2012
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2011N/A11
Nov 2011N/A13
Dec 2011N/A5
Jan 2012N/A6
Feb 2012N/A4
Mar 2012N/A7
Apr 2012N/A5
May 2012N/A6
Jun 2012N/A3
Jul 2012N/A4
Aug 2012N/A2
Sep 2012N/A6

FY 2012 Total: 72

Number of written meeting responses during the month that were faxed/emailed two FDA business days or less in advance of the meeting

Fiscal Year - 2012
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2011N/A2
Nov 2011N/A5
Dec 2011N/A0
Jan 2012N/A4
Feb 2012N/A1
Mar 2012N/A2
Apr 2012N/A1
May 2012N/A5
Jun 2012N/A1
Jul 2012N/A3
Aug 2012N/A6
Sep 2012N/A1

FY 2012 Total: 31

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.